

MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Octreotide - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.				
Member Name:		Prescriber Name:		
Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Line of Business:	□ Medicare Advantage	NPI:	State Lic ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Primary Phone:		Specialty/facility name (if applicable):		
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize he life or health of the enrollee or the enrollee's ability to regain maximum function.				
Drug Name:				
Strength:				
Directions / SIG:				
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.				
Q1. Is the request for octreotide for reauthorization?				
☐ Yes		□ No		
Q2. Has the patient had a positive clinical response to octreotide?				
☐ Yes		□ No		
Q3. Does the patient have a documented diagnosis of acromegaly?				
☐ Yes		□ No		
Q4. Is baseline insulin-like growth factor-1 (IGF-1) level for age and/or gender above the upper limit of normal based on laboratory reference range?				
☐ Yes		□ No		
Q5. Has the patient had an inadequate response to surgery or radiation therapy?				
☐ Yes		□No		
Q6. Is there a clinical reason why the patient has not had surgery or radiation therapy?				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Octreotide - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:			
□Yes	□ No			
Q7. Does the patient have a documented diagnosis of metastatic carcinoid tumor?				
☐ Yes	□ No			
Q8. Does the patient require symptomatic treatment of severe diarrhea or flushing episodes?				
☐ Yes	□ No			
Q9. Does the patient have a diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea?				
☐ Yes	□ No			
Q10. Is octreotide being prescribed by or in consultation with an endocrinologist, oncologist, or gastroenterologist?				
☐ Yes	□ No			
Q11. Requested Duration:				
☐ 12 Months	☐ Other			
Q12. Additional Information:				
Prescriber Signature	Date			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

v2025